Latest News / AZD9291 NewsStream Add Bookmark

Latest articles for AZD9291, as of Thu Jul 31.Want Email Updates? Just use the 'Daily Updates' box on the right!. Below that is a more extensive toolbox that allows you to filter and triage these articles.
Coloured tags show you key topics (e.g. Indications, Drugs, Targets, Companies) also mentioned in the article. Click a tag to see its own NewsStream, or the '' link to create a NewsStream that specifically mentions the two topics together.


 
Astrazeneca And Roche To Develop Diagnostic Test For Lung Cancer Drug - Zenopa

Drug Web Reports  (Today)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Reaches Out To Roche With A WOULD-Be Cancer Blockbuster

FierceBiotech  (2 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca, Roche Collaborate On Companion Diagnostic Test - Drug Discovery & Development

Drug Web Reports  (2 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Initiates Cdx Partnerships With Roche, Qiagen - Genetic Engineering News

Drug Web Reports  (2 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca And Roche Announce Partnership To Develop Companion Diagnostic Test For AZD9291

EPR  (3 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Launches Cdx Partnerships With Roche, Qiagen - Genetic Engineering News

Drug Web Reports  (3 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Study To Assess The Effect Of Rifampicin On Blood Levels And Safety Of AZD9291, In Patients With Egfrm+ Nsclc

ClinicalTrials.gov Trial Updates Record#NCT02197247 [Sponsor:AstraZene...  (8 days ago)

Clinical Trial: Expand | View [This Window] [New Window]
 
Study To Assess The Effect Of AZD9291 On The Blood Levels Of Simvastatin In Patients With Egfrm+ Nsclc

ClinicalTrials.gov Trial Updates Record#NCT02197234 [Sponsor:AstraZene...  (8 days ago)

Clinical Trial: Expand | View [This Window] [New Window]
 
Study To Determine The Effect Of Food On The Blood Levels Of AZD9291 Following Oral Dosing Of A Tablet Formulation In Patients With NON-Small Cell Lung Cancer

ClinicalTrials.gov Trial Updates Record#NCT02163733 [Sponsor:AstraZene...  (45 days ago)

Clinical Trial: Expand | View [This Window] [New Window]
 
Investigational Drug AZD9291 Shows Clinical Responses In Patients With ... - Marketwatch

Drug Web Reports  (50 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Shows Promising Results Of AZD9291 And MEDI4736 Cancer ... - Tech Times

Drug Web Reports  (56 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Clovis Stabilizes After Big ASCO-Related Crash

Biomed Reports News  (56 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
AZD9291, An Irreversible Egfr Tki, Overcomes T790m-Mediated Resistance To Egfr Inhibitors In Lung Cancer

Cross DA et al Cancer Discov. 2014 Jun 3. pii: CD-14-0337.  (56 days ago)

Publication: Expand | View [This Window] [New Window]
 
 
Investigational Drug AZD9291 Shows Clinical Responses In Patients With ... - Canada Newswire (Press Release)

Drug Web Reports  (57 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
At Asco, NEXT-Gen Egfr Inhibitors Show Early Promise In Lung Cancer Patients With T790m Mutations

GenomeWebPgx  (59 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity And ... - Fiercebiotech

Drug Web Reports  (60 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Investigational Drug AZD9291 Shows Clinical Responses In Patients With ... - Pr Newswire Uk (Press Release)

Drug Web Reports  (61 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity And ... - Business Wire (Press Release)

Drug Web Reports  (61 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Rejects Raised Pfizer Bid; Stock Falls Azn Pfe - Investor's Business Daily

Drug Web Reports  (73 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Marginal Growth In R&D Spending By International Pharma Giants In Q1 - Pharmabiz.Com

Drug Web Reports  (73 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca's Lung Cancer AZD9291 Shrinks Tumor IN 50 Percent Of Patients ... - Tech Times

Drug Web Reports  (77 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Drug Shrinks Lung Cancers Typically Hardened By Genetic Mutation - Thestreet.Com

Drug Web Reports  (77 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Net Dips BY 36% In Q1 To $506 Million - Pharmabiz.Com

Drug Web Reports  (95 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Posts First Quarter Results - Cambridge Network

Drug Web Reports  (96 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Net Dips BY 36% In Q1 To $506 Million - Pharmabiz.Com

Drug Web Reports  (97 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca's Ceo Discusses Q1 2014 Results - Earnings Call Transcript - Seeking Alpha

Drug Web Reports  (97 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Reports On Continued Momentum - Cambridge News

Drug Web Reports  (97 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 
Astrazeneca Continues To Chop Back, Spotlights IMMUNO-Oncology Phiii - Fiercebiotech

Drug Web Reports  (98 days ago)

Web/News Item: Expand | View [This Window] [New Window]
 

Next >

Topic Activity [last 90 days]

Please wait... If the chart does not appear, try updating your browser, ensuring javasript is turned turned on

  Daily Alerts!

 Get Regular Updates By:  Email or RSS

[Need Help With RSS?]
 About This Topic  Data Mining Tools  My Recent Topics  Quick Help

Sponsored Links


Interested in sponsoring our site or advertising with us? Be a part of SciBites growing success. Contact Us Today.



View as RDF